Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Background: cost of anticoagulation with dabigatran is largely based on estimation of
complication rates derived from clinical trials. Objective: to investigate cost of anticoagulation …

Background To Estimate, in the context of a Health Department of the Valencia Health
Agency, the budgetary impact of the widespread use of dabigatran at doses of 110 and 150 …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …